Associated Genetic Biomarkers
Myelomas most frequently harbor alterations in KRAS, TP53, NRAS, TET2, and DNMT3A .
KRAS Mutation, TP53 Mutation, NRAS Mutation, TP53 c.217-c.1178 Missense, and TP53 Missense are the most common alterations in myeloma .
There are 6 clinical trials for myeloma, of which 6 are open and 0 are completed or closed. Of the trials that contain myeloma as an inclusion criterion, 1 is phase 1/phase 2 (1 open) and 5 are phase 2 (5 open).
IGH-FGFR3, StrucGain(1)(q21), and del(17)(p10) are the most frequent gene inclusion criteria for myeloma clinical trials .
Allogeneic hematopoietic stem cell transplantation, cyclophosphamide, and dexamethasone are the most common interventions in myeloma clinical trials.
Significant Genes in Myeloma
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.